Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536068 | 0.83 | ALDH1A1 (0.36) | NPSR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL381580 | 0.80 | NPSR1 (0.40) | NPSR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL29658422 | 0.80 | NPSR1 (0.40) | NPSR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL12376467 | 0.78 | — | — | |
| SCHEMBL12536072 | 0.74 | MAPT (0.43) | NPSR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL12536073 | 0.70 | ADORA2A (0.46) | NPSR1KDM4ELMNAALOX15HTT | |
| SCHEMBL12376462 | 0.69 | ADORA1 (0.30) | — | |
| SCHEMBL12376505 | 0.69 | — | — | |
| SCHEMBL12376487 | 0.67 | KDM4E (0.35) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL13429007 | 0.67 | RET (0.42) | NPSR1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| US-9205077-B2 | 2-alkoxy-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140296295-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8791146-B2 | 2-alkoxy-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8703934-B2 | Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8426602-B2 | Heteroaryl-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110136871-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20100069363-A1 | SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069363-A1 | SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, DDC, TPMT | NPSR1 4067/4885KDM4E 489/4885MEN1 3087/4885 |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | NPSR1 3419/4885KDM4E 2518/4885MEN1 3728/4885 |
| US-20110136871-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, TNNT2 | NPSR1 3804/4885KDM4E 2290/4885MEN1 2973/4885 |
| US-20140296295-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, TNNT2 | NPSR1 3804/4885KDM4E 2290/4885MEN1 2973/4885 |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, SDHA | NPSR1 3537/4885KDM4E 3532/4885MEN1 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.